0GT.F STOKE THERAPEUT.DL-001
- Market cap
- EUR 1.58B
- P/E
- -
- P/B
- 5.05x
- ROE
- -70.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0GT.F undervalued?
Graham numberThe Graham number of STOKE THERAPEUT.DL-001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
STOKE THERAPEUT.DL-001 fundamental analysis
No fundamental analysis for STOKE THERAPEUT.DL-001 yet.
STOKE THERAPEUT.DL-001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About STOKE THERAPEUT.DL-001
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001),…
Full company profileSTOKE THERAPEUT.DL-001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
STOKE THERAPEUT.DL-001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 12.4M | 8.78M | 36.6M | 184M | 35.7M |
| Operating Income | -86.1M | -104M | -115M | -101M | -20.6M | -262M |
| EBITDA | - | -103M | -112M | -99.2M | -18.8M | -260M |
| Net Income | -85.8M | -101M | -105M | -89.0M | -6.89M | -247M |
| EPS | -2.33 | -2.56 | -2.28 | -1.65 | -0.12 | -3.81 |
| Balance Sheet | ||||||
| Total Assets | 239M | 256M | 228M | 272M | 418M | 407M |
| Total Liabilities | 21.1M | 71.2M | 68.8M | 42.5M | 66.0M | 54.1M |
| Shareholders' Equity | 218M | 185M | 160M | 229M | 352M | 353M |
| Cash & Short-term Investments | 145M | 114M | 191M | 128M | 84.2M | 107M |
| Cash Flow | ||||||
| Operating Cash Flow | -66.9M | -31.9M | -81.1M | -86.9M | 45.6M | -240M |
| Capital Expenditure | 1.20M | 3.96M | 1.62M | 203K | 670K | 6.91M |
| Free Cash Flow | -68.1M | -35.8M | -82.7M | -87.1M | 44.9M | -247M |
| Ratios | ||||||
| ROE | -39.4% | -54.7% | -65.6% | -38.9% | -2.0% | -70.1% |
| ROA | -35.9% | -39.5% | -45.9% | -32.8% | -1.6% | -60.7% |
| Net Profit Margin | - | -814.7% | -1,192.5% | -243.4% | -3.7% | -691.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
STOKE THERAPEUT.DL-001 dividends
STOKE THERAPEUT.DL-001 has not paid dividends in the last 5 fiscal years.
Who owns STOKE THERAPEUT.DL-001
- Insiders 3.62%
- Institutions 96.38%
- Public & others 0.00%
- Shares outstanding 65.4M
- Free float 46.5M
STOKE THERAPEUT.DL-001 company profile
- Company name
- STOKE THERAPEUT.DL-001
- Ticker
- 0GT.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 170
- Fiscal year end
- December
- Address
- 45 Wiggins Avenue, Bedford, MA, United States, 01730
- Phone
- 781 430 8200
- Website
- stoketherapeutics.com
About STOKE THERAPEUT.DL-001
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
STOKE THERAPEUT.DL-001 management
10- Mr. Ian F. Smith A.C.A., C.P.A.CEO & Director · born 1966
- Dr. Adrian R. Krainer Ph.D.Co-Founder & Independent Director · born 1959
- Mr. Thomas Edward LeggettChief Financial Officer · born 1977
- Mr. Jason HoittChief Patient Officer · born 1978
- Ms. Isabel Aznarez Ph.D.Co-Founder & CTO · born 1972
- Dr. Thomas McCauley Ph.D.Chief Scientific Officer · born 1969
- Mr. Jonathan Allan J.D.Corporate Secretary, Compliance Officer & General Counsel · born 1990
- Susan WillsonVice President of Corporate Communications
- Ms. Sara Den BestenChief People Officer
- Dr. Barry S. Ticho FACC, M.D., Ph.D.Chief Medical Officer · born 1960